<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302742</url>
  </required_header>
  <id_info>
    <org_study_id>KUMC 12614</org_study_id>
    <nct_id>NCT02302742</nct_id>
  </id_info>
  <brief_title>Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry</brief_title>
  <acronym>PROGECT</acronym>
  <official_title>PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who
      have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being done to collect cancer-related information from patients with triple
      negative breast cancer and patients with hereditary genetic mutations. This information will
      help us better understand the link between genetic changes and cancer outcome in patients
      with triple negative breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence of germline mutations (such as BRCA1/2 mutations) in patients with TNBC</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>. Predictors of response to neo/adjuvant chemotherapy in patients with TNBC</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term Disease free and overall survival rates in TNBC patients treated with different systemic therapies</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hereditary Breast and Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer patients</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Germline HBOC Mutation Carriers</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A baseline blood draw is collected as a part of this registry. If a study participant has a
      personal history of cancer and a tumor sample is available, the participant may give consent
      for the tissue to be used as a part of the study. Additional optional specimen collection
      sub-studies may also be offered to participants.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Academic Center &amp; Community Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria include:

        Triple Negative Breast Cancer

          -  ER/PR &lt;10% and HER negative per current ASCO/CAP guidelines

          -  Stages I-IV

          -  Any age at diagnosis

          -  Patient must be within 5 years of diagnosis

          -  Eligible regardless of genetic testing status

          -  Genetic testing recommended for patients meeting NCCN and Medicare guidelines

        AND/OR

        Germline mutation Carriers

          -  Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53,
             -PALB2 etc) are eligible regardless of type/site of cancer

          -  Healthy patients harboring mutations also eligible

          -  There is no time limit from the time of diagnosis of cancer and enrollment.

          -  Eligible regardless of personal history of cancer

        Exclusion Criteria include:

        Triple Negative Breast Cancer -Patient is not within five years of diagnosis

        Germline mutation Carriers:

        -Patient only carries a HBOC mutation that is classified as &quot;polymorphism&quot; of &quot;favor
        polymorphism&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priyanka Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolyn Lehn</last_name>
    <phone>(913) 588-6079</phone>
    <email>clehn@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hays Medical Center Dreiling-Schmidt Cancer Institute</name>
      <address>
        <city>Hays</city>
        <state>Kansas</state>
        <zip>67601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josette Klaus</last_name>
      <phone>785-623-5761</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCCC West</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Sharpe-Pringle</last_name>
      <phone>913-328-3206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Nelson</last_name>
      <phone>913-498-7892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCCC Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Kuechler</last_name>
      <phone>913-234-0459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Overland Park Regional Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Nelson</last_name>
      <phone>913-498-7892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salina Regional Health Center - Tammy Walker Cancer Center</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Leepers, RN, MBA</last_name>
      <phone>785-452-7038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Wang</last_name>
      <phone>913-588-6079</phone>
      <email>ywang9@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karissa Finke</last_name>
      <phone>(913) 588- 6079</phone>
      <email>kfinke@kumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centerpoint Regional Medical Center</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Nelson</last_name>
      <phone>816-698-8249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Malomo</last_name>
      <phone>816-404-4093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCCC South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Harris-Connell</last_name>
      <phone>816-823-6640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Feeback</last_name>
      <phone>816-276-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCCC - North</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Jenci</last_name>
      <phone>816-584-4879</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KCCC Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Ward</last_name>
      <phone>816-350-5825</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. Epub 2014 May 7.</citation>
    <PMID>24807107</PMID>
  </results_reference>
  <results_reference>
    <citation>Connor CS, Kimler BF, Mammen JM, McGinness MK, Wagner JL, Alsop SM, Ward C, Fabian CJ, Khan QJ, Sharma P. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. J Surg Oncol. 2015 Feb;111(2):198-202. doi: 10.1002/jso.23790. Epub 2014 Sep 29.</citation>
    <PMID>25266871</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas</investigator_affiliation>
    <investigator_full_name>Priyanka Sharma</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>TNBC</keyword>
  <keyword>Hereditary Breast and Ovarian Cancer</keyword>
  <keyword>HBOC</keyword>
  <keyword>Prospective Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

